PDCD1 and neoplasm: Despite higher persistence of 4-1BB/CD3ζ CAR-T cells, statistically significant tumor control in vivo was only obtained when combining FAP-ΔCD28/CD3ζ CAR-T cells with the immune checkpoint PD-1 inhibitor antibodies (174).